September 2008
With its strategy focused on offering 24-hour turnaround time, the molecular diagnostic testing provider ViraCor Reference Lab (Kansas City, Mo.) is expecting revenues to climb to a $27 million in 2009, up 35 percent from this year’s revenue total of $20 million, company Vice President Bob Wilhelm explained at the American Association of Clinical Chemistry’s Annual Meeting and Clinical Expo, held July 27-31 in Washington, D.C.
|
Bob Wilhelm, vice president, ViraCor Reference Lab (Kansas City, Mo.)
 |
Specializing in infectious disease testing, most of ViraCor’s clients are from pediatric and academic medical institutions with specimens coming from patients with compromised immune systems, as well as a broad spectrum of transplant patients. Wilhelm estimates that his company partners with about 75 percent of the pediatric transplant hospitals in the United States. Their primary value proposition is quick turn-around time, which is especially vital for these patients. "We deliver a majority of our results in just eight hours or by 5pm client time, with all results available in less than 24 hours," he added.
Even with their growth—which has been between 35 percent and 50 percent over the past five years—ViraCor does not plan on extending far beyond their infectious disease testing focus, even though this segment of the molecular diagnostic market is believed to be slowing down after years of rapid growth. "Our intent is not to be all things to all people, we like to focus on the patient disease outcome for this group of patients," said Wilhelm.
|
September 2008 - Table of Contents
Archives